Abstract 987: Overexpression of 14-3-3α in cancer cells activates PI3K via binding the p85 regulatory subunit

Jia Xu,Christopher L. Neal,Ping Li,Seiji Mori,Jun Yang,Nina N. Neal,Xiaoyan Zhou,Shannon L. Wyszomierski,Dihua Yu
DOI: https://doi.org/10.1158/1538-7445.am2012-987
IF: 11.2
2012-01-01
Cancer Research
Abstract:Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL The ubiquitously expressed 14-3-3 proteins regulate many pathways involved in transformation. Previously, we found that 14-3-3α overexpression increased Akt phosphorylation in human mammary epithelial cells. Here, we investigated the clinical relevance and molecular mechanism of 14-3-3α overexpression-mediated Akt phosphorylation and the potential impact on breast cancer progression. We found that 14-3-3α overexpression was significantly (P = 0.005) associated with increased Akt phosphorylation in human breast tumors. Additionally, 14-3-3α overexpression combined with strong Akt phosphorylation was significantly (P=0.01) associated with increased cancer recurrence in patients. In contrast, knockdown of 14-3-3α expression by siRNA in cancer cell lines and tumor xenografts reduced Akt phosphorylation. Furthermore, 14-3-3α enhanced Akt phosphorylation through activation of PI3K. Mechanistically, 14-3-3α bound to the p85 regulatory subunit of PI3K and increased PI3K translocation to the cell membrane. A single 14-3-3 binding motif encompassing serine 83 on p85 is largely responsible for 14-3-3α-mediated p85 binding and PI3K/Akt activation. Mutation of serine 83 to alanine on p85 inhibited 14-3-3α binding to the p85 subunit of PI3K, reduced PI3K membrane localization and activation, impeded anchorage independent growth and enhanced stress induced apoptosis. These findings revealed a novel mechanism by which 14-3-3α overexpression activates PI3K, a key node in the mitogenic signaling network known to promote malignancies in many cell types. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 987. doi:1538-7445.AM2012-987
What problem does this paper attempt to address?